Andrew Smith1, Mercy Pawar1, Marcian E Van Dort2,3, Stefanie Galbán2,3, Amanda R Welton2,3, Greg M Thurber4, Brian D Ross2,3,5, Cagri G Besirli1. 1. 1 Department of Ophthalmology and Visual Sciences, University of Michigan , Medical School, Ann Arbor, Michigan. 2. 2 Department of Radiology and Biological Chemistry, Center for Molecular Imaging, University of Michigan , Medical School, Ann Arbor, Michigan. 3. 3 Department of Radiology, University of Michigan , Medical School, Ann Arbor, Michigan. 4. 4 Department of Chemical Engineering, University of Michigan , Medical School, Ann Arbor, Michigan. 5. 5 Department of Biological Chemistry, University of Michigan , Medical School, Ann Arbor, Michigan.
Abstract
PURPOSE: ST-162 and ST-168 are small-molecule bifunctional inhibitors of MEK and PI3K signaling pathways that are being developed as novel antitumor agents. Previous small-molecule and biologic MEK inhibitors demonstrated ocular toxicity events that were dose limiting in clinical studies. We evaluated in vitro and in vivo ocular toxicity profiles of ST-162 and ST-168. METHODS: Photoreceptor cell line 661W and adult retinal pigment epithelium cell line ARPE-19 were treated with increasing concentrations of bifunctional inhibitors. Western blots, cell viability, and caspase activity assays were performed to evaluate MEK and PI3K inhibition and dose-dependent in vitro toxicity, and compared with monotherapy. In vivo toxicity profile was assessed by intravitreal injection of ST-162 and ST-168 in Dutch-Belted rabbits, followed by ocular examination and histological analysis of enucleated eyes. RESULTS: Retinal cell lines treated with ST-162 or ST-168 exhibited dose-dependent inhibition of MEK and PI3K signaling. Compared with inhibition by monotherapies and their combinations, bifunctional inhibitors demonstrated reduced cell death and caspase activity. In vivo, both bifunctional inhibitors exhibited a more favorable toxicity profile when compared with MEK inhibitor PD0325901. CONCLUSIONS: Novel MEK and PI3K bifunctional inhibitors ST-162 and ST-168 demonstrate favorable in vitro and in vivo ocular toxicity profiles, supporting their further development as potential therapeutic agents targeting multiple aggressive tumors.
PURPOSE: ST-162 and ST-168 are small-molecule bifunctional inhibitors of MEK and PI3K signaling pathways that are being developed as novel antitumor agents. Previous small-molecule and biologic MEK inhibitors demonstrated ocular toxicity events that were dose limiting in clinical studies. We evaluated in vitro and in vivo ocular toxicity profiles of ST-162 and ST-168. METHODS: Photoreceptor cell line 661W and adult retinal pigment epithelium cell line ARPE-19 were treated with increasing concentrations of bifunctional inhibitors. Western blots, cell viability, and caspase activity assays were performed to evaluate MEK and PI3K inhibition and dose-dependent in vitro toxicity, and compared with monotherapy. In vivo toxicity profile was assessed by intravitreal injection of ST-162 and ST-168 in Dutch-Belted rabbits, followed by ocular examination and histological analysis of enucleated eyes. RESULTS: Retinal cell lines treated with ST-162 or ST-168 exhibited dose-dependent inhibition of MEK and PI3K signaling. Compared with inhibition by monotherapies and their combinations, bifunctional inhibitors demonstrated reduced cell death and caspase activity. In vivo, both bifunctional inhibitors exhibited a more favorable toxicity profile when compared with MEK inhibitor PD0325901. CONCLUSIONS: Novel MEK and PI3K bifunctional inhibitors ST-162 and ST-168 demonstrate favorable in vitro and in vivo ocular toxicity profiles, supporting their further development as potential therapeutic agents targeting multiple aggressive tumors.
Authors: Patricia M LoRusso; Smitha S Krishnamurthi; John J Rinehart; Lisle M Nabell; Lisa Malburg; Paul B Chapman; Samuel E DePrimo; Steven Bentivegna; Keith D Wilner; Weiwei Tan; Alejandro D Ricart Journal: Clin Cancer Res Date: 2010-03-09 Impact factor: 12.531
Authors: Klaus P Hoeflich; Mark Merchant; Christine Orr; Jocelyn Chan; Doug Den Otter; Leanne Berry; Ian Kasman; Hartmut Koeppen; Ken Rice; Nai-Ying Yang; Stefan Engst; Stuart Johnston; Lori S Friedman; Marcia Belvin Journal: Cancer Res Date: 2011-11-14 Impact factor: 12.701
Authors: Alexa B Turke; Youngchul Song; Carlotta Costa; Rebecca Cook; Carlos L Arteaga; John M Asara; Jeffrey A Engelman Journal: Cancer Res Date: 2012-05-02 Impact factor: 12.701
Authors: Terence M Williams; Athena R Flecha; Paul Keller; Ashwin Ram; David Karnak; Stefanie Galbán; Craig J Galbán; Brian D Ross; Theodore S Lawrence; Alnawaz Rehemtulla; Judith Sebolt-Leopold Journal: Mol Cancer Ther Date: 2012-03-12 Impact factor: 6.261
Authors: Marcian E Van Dort; Stefanie Galbán; Hanxiao Wang; Judith Sebolt-Leopold; Christopher Whitehead; Hao Hong; Alnawaz Rehemtulla; Brian D Ross Journal: Bioorg Med Chem Date: 2015-03-06 Impact factor: 3.641
Authors: Hua Zhong; Cesar Sanchez; Dirk Spitzer; Dirk Spitrzer; Stacy Plambeck-Suess; Jesse Gibbs; Williams G Hawkins; David Denardo; Feng Gao; Robert A Pufahl; Albert C Lockhart; Mai Xu; David Linehan; Jason Weber; Andrea Wang-Gillam Journal: PLoS One Date: 2013-10-09 Impact factor: 3.240
Authors: Thomas J Wubben; Mercy Pawar; Eric Weh; Andrew Smith; Peter Sajjakulnukit; Li Zhang; Lipeng Dai; Heather Hager; Manjunath P Pai; Costas A Lyssiotis; Cagri G Besirli Journal: Sci Rep Date: 2020-02-19 Impact factor: 4.379